Court of Appeals Rules on Mifepristone Case, Feminist Women’s Health Center Continues to Provide Medication Abortion

April 14th, 2023

Contact: MK Anderson
marketing@feministcenter.org

Atlanta, Georgia – On Wednesday, April 12th, the Court of Appeals for the 5th Circuit ruled on Alliance for Hippocratic Medicine v. FDA, which challenged the FDA’s approval for medication abortion pill mifepristone. The FDA approved mifepristone in 2000 after years of rigorous testing and study.

The Court of Appeals ruled to partially uphold the FDA’s approval of mifepristone while litigation is still pending, but it struck down the FDA’s provisions allowing the medication to be mailed. The court also held that mifepristone could only be used up for up to 11 weeks of pregnancy, and it noted that the generic version of mifepristone could be subject to further restrictions in the future.

Regardless of the case’s disposition, Feminist Women’s Health Center will continue to provide medication abortion in compliance with FDA the law. FWHC’s Executive Director Kwajelyn Jackson says:

“These challenges to mifepristone are misguided attempts to confuse the people about the pill’s safety and legal status. But make no mistake: mifepristone has been subject to over 20 years of rigorous testing study, and use. Decades of research tell us that the pill is a safe option for abortion care, just as the FDA has already determined. Feminist Women’s Health Center will continue offering medication and surgical abortion care, and we will continue educate our communities on all available options.”

###